1Loescher, W, Levy, RH, Mattson, RH, Meldrum, BS, Perucca, E, (eds). Valproic acid mechanisms of action. In Antiepileptic Drugs: 767–79. Lippincott Williams & Wilkins, 2002.
2Fountoulakis, KN, Vieta, E, Sanchea-Morena, J, Kaprinis, SG, Goikolea, JM, Kaprinis, GS. Treatment guidelines for bipolar disorder: a critical review. J Affect Disord 2005; 86: 1–10.
3Bowden, CL. Valproate. Bipolar Disord 2003; 5: 189–202.
4Meador, KJ. Neurodevelopmental effects of antiepileptic drugs. Current Neurol Neurosci Rep 2002; 2: 373–8.
5Tomson, T, Marson, A, Boon, P, Canevini, MP, Covanis, A, Gaily, E, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsua 2015; 56(7): 1006–19.
6Omtzigt, J, Los, FJ, Hagenaars, AM, Stewart, PA, Sachs, ES, Lindhout, D. Prenatal diagnosis of spina bifida aperta after first trimester valproate exposure. Prenat Diagn 1992; 12: 893–7.
7Hrubec, TC, Yan, M, Keying, Y, Salafia, CM, Holladay, SD. Valproic acid induced fetal malformations are reduced by maternal immune stimulation with granulocyte-macrophage colony–stimulating factor or interferon Y. Anat Rec Discov Mol Cell Evol Biol 2006; 288: 1303–9.
8Cragan, JD, Roberts, HE, Edmonds, LD, Khoury, MJ, Kirby, RS, Shaw, GM, et al. Surveillance for anencephaly and spina bifida and the impact of prenatal diagnosis–United States, 1985-1994. MMWR CDC Surveill Summ 1995; 44: 1–13.
9Adab, N, Kini, U, Vinten, J, Ayres, J, Baker, G, Clayton-Smith, J, et al. The longer-term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004; 75: 1575–83.
10Chiu, CT, Wang, Z, Hunsberger, JG, Chuang, DM. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev 2013; 65: 105–42.
11DiLiberti, JH, Farndon, PA, Dennis, NR, Curry, CJ. The fetal valproate syndrome. Am J Med Genet 1984; 19: 473–81.
12Meador, KJ, Baker, GA, Finnell, RH, Kalayjian, LA, Liporace, JD, Loring, DW, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006; 67: 407–12.
13Alsdorf, R, Wyszynski, DF. Teratogenicity of sodium valproate. Expert Opinion Drug Saf 2005; 4: 345–53.
14James, L, Barnes, TRE, Lelliott, P, Taylor, D, Paton, C. Informing patients of the teratogenic potential of mood stabilising drugs: a case note review of the practice of psychiatrists. J Psychopharmacol 2007; 21: 815–9.
15Langan, J, Perry, A, Oto, M. Teratogenic risk and contraceptive counselling in psychiatric practice: analysis of anticonvulsant therapy. BMC Psychiatry 2013; 13: 234.
16Attura, H, Odelola, A. Valproate prescribing in women of child bearing age: an audit of clinical practice. Adv Psychiatry 2015; 2015: 520784.
17James, L, Paton, C, Lelliott, P, Barnes, TRE, Taylor, D. Mood stabilizers and teratogenicity-prescribing practice and awareness among practicing psychiatrists. J Ment Health 2009; 18: 137–43.
18ICD-10 Classification of Mental and Behavioural Disorders, Churchill Livingstone, Elsevier Limited, 1994.
20Viguera, AC, Cohen, LS, Bouffard, S, Whitfield, TH, Baldessarini, RJ. Reproductive decisions by women with bipolar disorder after pregnancy psychiatric consultation. Am J Psychiatry 2002; 159: 2102–4.